Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) in a research report sent to investors on Friday,Benzinga reports.

VIGL has been the topic of a number of other research reports. JMP Securities restated a "market outperform" rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Vigil Neuroscience in a research report on Thursday. William Blair began coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They set an "outperform" rating on the stock. Finally, Wedbush raised their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $19.75.

Vigil Neuroscience Trading Down 6.4 %

Shares of VIGL stock traded down $0.15 during trading hours on Friday, hitting $2.20. The company's stock had a trading volume of 3,453,177 shares, compared to its average volume of 213,436. The business has a fifty day moving average of $2.08 and a 200-day moving average of $3.11. The stock has a market cap of $89.94 million, a price-to-earnings ratio of -1.07 and a beta of 1.76. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.08. On average, equities analysts expect that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

A number of large investors have recently bought and sold shares of VIGL. Renaissance Technologies LLC raised its stake in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock worth $286,000 after purchasing an additional 11,536 shares during the period. Ensign Peak Advisors Inc lifted its holdings in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock worth $1,580,000 after buying an additional 166,442 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vigil Neuroscience in the 2nd quarter worth about $87,000. Point72 Asset Management L.P. bought a new stake in shares of Vigil Neuroscience during the 2nd quarter valued at about $5,940,000. Finally, abrdn plc bought a new stake in shares of Vigil Neuroscience during the 3rd quarter valued at about $799,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.